VIVAXIM SOLUTION Canadá - inglés - Health Canada

vivaxim solution

sanofi pasteur limited - salmonella typhi vi capsular polysaccharide vaccine; hepatitis a vaccine, inactivated - solution - 25mcg; 160unit - salmonella typhi vi capsular polysaccharide vaccine 25mcg; hepatitis a vaccine, inactivated 160unit - vaccines

SCABIVAX CONTAGIOUS PUSTULAR DERMATITIS (ORF) VACC Irlanda - inglés - HPRA (Health Products Regulatory Authority)

scabivax contagious pustular dermatitis (orf) vacc

schering plough limited - contagious pustular dermatitis vaccine - suspension for skin scarification - ovine - immunological - live vaccine

SCABIVAX CONTAGIOUS PUSTULAR DERMATITIS (ORF) VACCINE Irlanda - inglés - HPRA (Health Products Regulatory Authority)

scabivax contagious pustular dermatitis (orf) vaccine

intervet ireland limited - contagious pustular dermatitis vaccine - suspension for skin scarification - per cent - orf virus vaccine / contagious pustular dermatitis vaccine - ovine - immunological - live vaccine

Scabivax Contagious pustular dermatitis (Orf) vaccine Suspension for skin scarification Irlanda - inglés - HPRA (Health Products Regulatory Authority)

scabivax contagious pustular dermatitis (orf) vaccine suspension for skin scarification

intervet ireland limited - contagious pustular dermatitis - cutaneous suspension - . - orf virus / contagious pustular dermatitis - sheep - immunological - live vaccine

RIVAXOTOR 10 rivaroxaban 10 mg tablet blister pack Australia - inglés - Department of Health (Therapeutic Goods Administration)

rivaxotor 10 rivaroxaban 10 mg tablet blister pack

arrotex pharmaceuticals pty ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; magnesium stearate; hypromellose; titanium dioxide; iron oxide red; macrogol 3350 - ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe